Research Gaps in Gastrointestinal Surgery - Viable Meta-Analysis Topics (Zero to Near-Zero Publications)

TIER 1 - CONFIRMED ZERO META-ANALYSES (PubMed returns 0 results)

1. Associations/Relationships

• Gap confirmed: Zero meta-analyses exist combining gut microbiome profiling data with anastomotic leak as a primary surgical outcome after colorectal resection
• Why it matters: Anastomotic leak carries 6-22% mortality. Microbiome shifts (particularly Fusobacterium nucleatum, Bacteroides fragilis) are biologically plausible drivers, but no pooled synthesis exists
• Feasible because: Individual RCTs and cohort studies on colonic microbiota composition exist; the meta-analytic synthesis is the missing layer
• Central question: Is preoperative gut microbiome composition (measured by 16S rRNA sequencing or culture-based methods) independently associated with anastomotic leak after colorectal surgery?

2. Causes & Effects

• Gap confirmed: Zero meta-analyses on this exact exposure-outcome pair
• Why it matters: GLP-1 agonists (semaglutide, liraglutide) are now among the most-prescribed drug classes globally. They delay gastric emptying, alter GI motility, and affect healing - yet no pooled surgical outcomes data exists. Anesthesiologists are raising aspiration concerns; surgeons have no pooled evidence on anastomotic or wound outcomes
• Central question: Does preoperative GLP-1 RA exposure independently increase the risk of postoperative complications (anastomotic leak, delayed gastric emptying, aspiration, wound dehiscence) in elective GI surgery patients?
• This is a highly publishable gap given the explosive rise of GLP-1 RA prescriptions globally since 2023

3. Rates & Trends

• Gap confirmed: Zero meta-analyses specifically examining visceral obesity (CT-measured visceral fat area) as a predictor of SSI, conversion to open, and length of stay after appendectomy
• Why it matters: Obesity is typically classified by BMI, which is a poor surrogate for surgical risk. Visceral fat area (measured on preoperative CT) is a precise anatomical marker but pooled rates for its impact on appendectomy outcomes are unknown
• Central question: What is the pooled incidence of postoperative surgical site infection and open conversion in patients with CT-defined visceral obesity undergoing laparoscopic appendectomy, and have these rates changed over the last decade?

4. Constructs & Categories

• Gap confirmed: While frailty in colorectal surgery has been studied, no meta-analysis exists that specifically compares frailty measurement tools (Clinical Frailty Scale, FRAIL scale, Edmonton Frail Scale, Fried phenotype) against each other in terms of outcome prediction validity - this is a construct/category-type gap
• Central question: Do different frailty classification tools predict 30-day vs. 1-year postoperative mortality and morbidity differentially in patients undergoing colorectal cancer surgery, and which tool has superior discriminatory validity?

TIER 2 - NEAR-ZERO (1-3 publications, update or expansion clearly needed)

5. Associations/Relationships

• Gap confirmed: Zero meta-analyses on psychological morbidity as a predictor of QoL in non-bariatric GI surgery (colectomy, gastrectomy, esophagectomy)
• The bariatric surgery mental health literature is more developed, but the same question for colorectal resection, gastric resection, and esophageal surgery is completely unmapped at a meta-analytic level
• Central question: Is preoperative depression or anxiety disorder independently associated with worse long-term health-related quality of life (HRQOL) at 12 months post-surgery in patients undergoing curative-intent gastrointestinal oncological surgery?

6. Rates & Trends

• Gap confirmed: The broader anastomotic leak literature is saturated for high-income settings; LMIC-specific pooled data and trend analysis is essentially absent
• Why it matters: Surgical capacity in LMICs is expanding rapidly; outcomes data for esophagectomy specifically in resource-limited environments is needed for global health planning
• Central question: What is the pooled anastomotic leak rate after esophagectomy performed in LMICs, and has it changed over the past 15 years with the adoption of minimally invasive techniques?

7. Causes & Effects

• Gap: Omega-3 immunonutrition meta-analyses exist for general surgery or ICU patients, but the narrow, specific question of elective colorectal surgery with infectious complications and CRP/IL-6 trajectory as dual outcomes has not been pooled
• Central question: Does preoperative omega-3 fatty acid supplementation (dose >2g/day for ≥5 days) reduce postoperative CRP, IL-6, and infectious complication rates in patients undergoing elective colorectal resection compared to standard nutritional preparation?

8. Constructs & Categories

• Emerging gap: A 2025 SAGES meta-analysis (PMID: 41188413) covered ICG fluorescence broadly, but no study has attempted to taxonomize and classify the indication categories (perfusion assessment, lymph node mapping, biliary anatomy, tumor localization) and pool their accuracy metrics separately by indication type
• Central question: What is the pooled diagnostic accuracy of ICG-fluorescence imaging for each distinct indication category in GI surgery, and can a validated classification framework for indications be derived from existing evidence?

9. Associations/Relationships (Rare Population)

• Gap: Transplant recipients undergo colorectal surgery for diverticulitis, colorectal cancer (excess risk on immunosuppression), and post-transplant lymphoproliferative disease complications. No meta-analysis synthesizes their surgical complication profile vs. immunocompetent patients
• Central question: In solid organ transplant recipients on maintenance immunosuppression, what is the pooled rate of anastomotic leak, SSI, and 30-day mortality after colorectal surgery compared to non-transplant patients?

10. Causes & Effects (Patient Safety)

• Gap: WHO SSC literature for GI surgery specifically in Sub-Saharan Africa is nearly absent at a meta-analytic level. A 2025 Frontiers review (found in web search) identified implementation barriers but stopped short of pooling outcomes data
• Central question: Does documented full compliance with the WHO Surgical Safety Checklist significantly reduce 30-day postoperative complication and mortality rates in gastrointestinal surgery performed in Sub-Saharan Africa?

HOW TO CONFIRM ZERO PUBLICATIONS BEFORE SUBMISSION

Priority Recommendations by Feasibility

Full Source Verification Report + New Research Gaps in GI Surgery Meta-Analysis

SECTION 1 - STATUS OF THE 10 PREVIOUSLY PROPOSED TOPICS

TOPIC 1 - GLP-1 Receptor Agonists + Elective GI Surgery Postoperative Outcomes

• A PROSPERO-registered meta-analysis on GLP-1 RA safety in general elective surgery (all specialties) - PROSPERO ID CRD420251027809, published at PMC
• A Frontiers Medicine meta-analysis on GLP-1 RA in IBD-related surgery specifically (PROSPERO CRD420251015882, August 2025)
• A BMC Plastic Surgery meta-analysis on body contouring surgery only (CRD420251140354, 2026)
• A Clinical Endoscopy meta-analysis on GLP-1 RA and colonoscopy bowel preparation outcomes (2026)

"Effect of preoperative GLP-1 receptor agonist use on anastomotic integrity and anastomotic leak rates specifically in elective colorectal and upper GI oncological surgery: a systematic review and meta-analysis"

TOPIC 2 - Gut Microbiome + Anastomotic Leak After Colorectal Surgery

• BJS Open 2025 (PMID: 41957947) - systematic review on gut microbiome and colorectal anastomotic leakage - published March 2025
• Frontiers Immunology 2025 (PMID: 41668765) - systematic review (not meta-analysis)
• A 2023 systematic review on collagenase-producing bacteria (PMID: 38038731)
• A 2019 broader systematic review (PMID: 31791356)

"Gut microbiome composition (specific taxa profiles) as an independent predictor of anastomotic leak: a meta-analysis with pooled odds ratios"

TOPIC 3 - Frailty Tool Comparison in Colorectal Cancer Surgery

TOPIC 4 - Immunosuppressed Transplant Recipients Undergoing Colorectal Surgery

"Outcomes of colorectal surgery in liver transplant recipients vs. renal transplant recipients: a comparative meta-analysis of anastomotic leak, SSI, and 30-day mortality"

TOPIC 5 - Preoperative Depression/Anxiety + Long-Term QoL After Non-Bariatric GI Surgery

TOPIC 6 - Esophagectomy Outcomes in Low- and Middle-Income Countries

TOPIC 7 - Omega-3 Immunonutrition + Colorectal Surgery (Infection + Inflammatory Markers)

TOPIC 8 - ICG Fluorescence Indication Classification (Taxonomy Meta-Analysis)

TOPIC 9 - Chronic Preoperative Opioid Use + Colorectal Surgery Outcomes

TOPIC 10 - Racial/Ethnic Disparities in GI Surgical Outcomes

"Racial and ethnic disparities in 30-day postoperative morbidity and mortality after colorectal cancer surgery in the United States: a meta-analysis of population-based studies"

SECTION 2 - NEW TOPICS (ADDITIONAL GAPS IDENTIFIED)

NEW TOPIC A - Causes & Effects

• Gap: ERAS meta-analyses pool all patients together. No meta-analysis stratifies ERAS outcomes (LOS, complication rates, readmission) by baseline frailty status. The question is whether frail patients derive equal benefit from ERAS pathways - a fundamental unanswered question.
• Central question: Does baseline frailty status modify the effect of ERAS protocol compliance on 30-day postoperative outcomes in patients undergoing colorectal surgery?
• Confirmed zero publications on this ERAS-frailty interaction at meta-analytic level

NEW TOPIC B - Rates & Trends

• Gap: Port-site metastasis is a feared but rare complication after laparoscopic colorectal cancer surgery. Individual series report rates of 0.5-1.8% but no pooled analysis exists. Risk factors (T stage, perforation, CO2 pressure, trocar type) have never been meta-analytically synthesized.
• Central question: What is the pooled incidence of port-site metastasis after laparoscopic colorectal cancer resection, and which intraoperative factors are independently associated with its occurrence?
• Evidence base: Multiple single-center series in Surgical Endoscopy, Colorectal Disease, Techniques in Coloproctology

NEW TOPIC C - Associations/Relationships

• Gap: Hypoalbuminemia as a general predictor of complications has been studied, but no dose-response meta-analysis has quantified the threshold effect (e.g., is <3.0 vs. <3.5 g/dL the meaningful cutpoint?) for anastomotic leak specifically. This is a PICO-precise question with a rich individual study pool and a clinically actionable answer.
• Central question: What is the dose-response relationship between preoperative serum albumin level and anastomotic leak risk after colorectal surgery, and what albumin threshold confers the greatest risk elevation?

NEW TOPIC D - Construct & Categories

• Gap: While individual comparisons exist, no network meta-analysis (NMA) has simultaneously compared all anastomotic configurations (intracorporeal vs. extracorporeal, hand-sewn vs. stapled, side-to-side vs. end-to-end) in right hemicolectomy in a single coherent evidence synthesis. An NMA would produce a ranking of safest anastomotic configuration - directly actionable for surgical practice.
• Central question: In laparoscopic right hemicolectomy, which anastomotic technique configuration is associated with the lowest pooled anastomotic leak rate when all technique variations are simultaneously compared in a network meta-analysis?
• Note: Individual comparisons of two techniques exist; a 3+ arm NMA does not

NEW TOPIC E - Causes & Effects

• Gap: Intraoperative hypothermia is a modifiable risk factor associated with impaired neutrophil function and wound healing. Multiple RCTs and cohort studies exist, but a focused meta-analysis examining colorectal surgery specifically (as opposed to mixed surgical populations) with SSI as the primary outcome has not been published.
• Central question: Does intraoperative hypothermia (core temperature <36°C) independently increase the risk of surgical site infection in elective colorectal surgery, and what is the pooled risk estimate?

NEW TOPIC F - Rates & Trends (Pediatric/Rare Population)

• Gap: Pediatric obesity rates have risen sharply. No meta-analysis pools reoperation, SSI, and perforation-related complication rates specifically for obese pediatric patients (BMI >95th percentile for age) undergoing laparoscopic appendectomy - distinct from adult populations in both physiology and technique.
• Central question: In pediatric patients with obesity (BMI >95th percentile), what is the pooled incidence of postoperative SSI, conversion to open surgery, and 30-day reoperation after laparoscopic appendectomy?

SECTION 3 - MASTER TABLE: FULL VERIFICATION SUMMARY

TOP 5 PRIORITY PICKS (Feasibility + Impact + Novelty)

1. Gut microbiome (pooled OR) + anastomotic leak - Foundational SRs already done; the meta-analytic synthesis is the natural next step and highly publishable in BJS, Annals of Surgery, or Colorectal Disease
2. Preoperative depression/anxiety + long-term QoL in non-bariatric GI surgery - Clean PICO, no competition, high clinical relevance for surgical oncology units, suitable for JAMA Surgery or Annals of Surgical Oncology
3. Albumin dose-response + anastomotic leak - Actionable clinical threshold answer, large primary study pool, dose-response methodology adds rigor
4. Frailty tool comparison in colorectal cancer surgery - Immediately implementable result for surgical practice; suitable for Journal of the American College of Surgeons or Diseases of the Colon & Rectum
5. Chronic preoperative opioid use + colorectal surgery outcomes - Strong US NSQIP/ACS study pool available, policy-relevant given opioid epidemic context, zero competition

ctDNA as a Prognostic Marker in Pan-GI Surgery - Full Source Verification & Recommendation

THE HONEST VERDICT UPFRONT

SECTION 1 - WHAT HAS ALREADY BEEN PUBLISHED (The Occupied Landscape)

SECTION 2 - WHERE THE GENUINE GAPS ARE (Zero Publications Confirmed)

GAP 1 - THE STRONGEST OPTION

• Every existing meta-analysis uses a single binary timepoint: ctDNA positive vs. negative at one postoperative measurement
• No meta-analysis has pooled the prognostic value of serial ctDNA trajectory patterns - specifically: (1) sustained negativity, (2) clearance (positive-to-negative), (3) persistently positive, (4) conversion (negative-to-positive during surveillance)
• Individual large trials (GALAXY, BESPOKE CRC, DYNAMIC) have reported these kinetic patterns, and HRs vary dramatically: rising ctDNA HR = 124.38 vs. clearance HR = 3.87 (from the ASCO 2026 CRC data), but these have never been pooled across GI cancer types
• A meta-analysis pooling the 4-pattern kinetic classification and their respective recurrence HRs across colorectal, gastric, esophageal, and pancreatic post-surgical cohorts would be genuinely novel

GAP 2 - STRONG OPTION

• Individual studies report lead times: 3-7 months (lung literature), 9.4 months (CRC), 212 days (212.5 days in one cohort) - but these are single-study estimates, never pooled across GI cancer types
• No meta-analysis has synthesized a single pooled lead-time estimate (with 95% CI) for the interval between ctDNA positivity and radiological diagnosis of recurrence across GI surgical cohorts
• This is a clinically actionable outcome: surgeons and oncologists need a pooled figure to design surveillance intervals

GAP 3 - VIABLE OPTION

• The biliary tract ctDNA meta-analysis (Boggio 2025) covers biliary tract (CCA, gallbladder) but explicitly excludes HCC
• The narrative review in Translational Gastroenterology and Hepatology (2026) discusses HCC ctDNA but does not include a meta-analysis
• HCC is surgically distinct (liver resection vs. transplantation vs. ablation), and individual HCC ctDNA studies exist but have never been pooled for the resection context specifically

GAP 4 - METHODOLOGICAL GAP (Novel Angle)

• ddPCR is mutation-specific, highly sensitive but limited to known variants; NGS (tumor-informed or tumor-agnostic) is broader but less sensitive per variant
• No meta-analysis has directly compared the sensitivity, specificity, and prognostic concordance of these two detection methods in GI surgical populations
• With standardization of ctDNA testing being a major unsolved clinical barrier, a method-comparison meta-analysis would have high practical impact

SECTION 3 - FINAL RECOMMENDATION

Should you pursue a ctDNA meta-analysis in pan-GI surgery?

The single best gap to pursue:

• Novel in framing: no existing meta-analysis pools the 4-pattern trajectory classification
• Built on existing rich data: GALAXY, BESPOKE, DYNAMIC, and equivalent studies in gastric/esophageal already exist to draw from
• Immediately actionable: the result would directly inform adjuvant chemotherapy decision-making (whether to treat ctDNA-clearance patients the same as sustained-negative patients)
• High-impact journal ready: Annals of Surgery, JAMA Oncology, Annals of Oncology, or eBioMedicine are all realistic targets
• PROSPERO unoccupied: register immediately before someone else does

ctDNA Serial Kinetics After GI Surgery - Explained Simply

Start with the basic idea: What is ctDNA?

What happens when a surgeon removes the tumor?

Sometimes ctDNA disappears cleanly. Sometimes it doesn't. Sometimes it disappears and then comes back. And each of those patterns means something completely different for the patient's future.

The 4 trajectory patterns - the core of the research idea

Pattern 1 - Sustained Negativity ✅ (Best case)

Before surgery:  ctDNA [HIGH]
After surgery:   ctDNA [ZERO]
3 months:        ctDNA [ZERO]
6 months:        ctDNA [ZERO]
1 year:          ctDNA [ZERO]

Pattern 2 - Clearance (Positive → Negative) 🟡 (Intermediate)

Before surgery:  ctDNA [HIGH]
2 weeks after:   ctDNA [LOW - still detectable]
3 months:        ctDNA [ZERO]
6 months:        ctDNA [ZERO]

Pattern 3 - Persistent Positivity 🔴 (Bad)

Before surgery:  ctDNA [HIGH]
2 weeks after:   ctDNA [STILL HIGH]
3 months:        ctDNA [STILL HIGH]
6 months:        ctDNA [STILL HIGH]

Pattern 4 - Conversion (Negative → Positive) 🔴🔴 (Worst case)

Before surgery:  ctDNA [HIGH]
2 weeks after:   ctDNA [ZERO - looks cured!]
3 months:        ctDNA [ZERO]
6 months:        ctDNA [DETECTABLE AGAIN - alarm!]

Why does this matter clinically?

So what's the actual research gap?

"Across all GI cancers - colorectal, gastric, esophageal, pancreatic, liver - what is the combined/pooled risk of recurrence for each pattern?"

• GALAXY trial (colorectal): ctDNA conversion pattern HR = 124 for recurrence
• BESPOKE trial (colorectal): clearance patients HR = 3.87 vs. sustained negative
• Gastric cancer studies: similar patterns reported
• Esophageal studies: similar patterns reported

Why is it a meta-analysis specifically?

Why is this specifically a GAP right now?

1. The technology just matured - sensitive ctDNA assays (like tumor-informed NGS and ddPCR) only became widely available in research settings around 2019-2022, so enough primary studies have only recently accumulated to make a meta-analysis feasible
2. Everyone has studied single cancer types - the colorectal literature is richest, gastric has a few papers, esophageal has a few, pancreatic has some. No one has stepped back and asked the cross-cancer pan-GI question
3. The kinetics angle is new - earlier meta-analyses used a simple binary question ("was ctDNA positive or negative?"). The richer 4-pattern trajectory question is a newer way of framing the data that no meta-analysis has adopted yet

In one sentence:

This meta-analysis would be the first to pool all the world's data on how ctDNA levels change over time after GI cancer surgery, and tell us precisely how much each pattern of change predicts whether the cancer will come back - giving oncologists a decision tool based on thousands of patients rather than dozens.

Inclusion & Exclusion Criteria for Primary Studies

Meta-Analysis: Prognostic Value of Perioperative ctDNA Kinetics (Serial Clearance Trajectories) After Curative-Intent Resection Across GI Cancers

PICO Framework (the backbone of the criteria)

INCLUSION CRITERIA

1. Study Design

2. Population

3. Cancer Types (GI Spectrum)

4. ctDNA Assessment - The Central Eligibility Criterion

5. Outcomes

6. Language and Publication Period

EXCLUSION CRITERIA

Study Design Exclusions

Population Exclusions

ctDNA Method Exclusions

Outcome Exclusions

HANDLING SPECIAL CASES (pre-specified decisions)

Summary Table at a Glance

Part 1 - How to Search PROSPERO + What I Found

How to search PROSPERO yourself (step-by-step)

1.  ctDNA AND kinetics AND gastrointestinal
2.  ctDNA AND trajectory AND surgery
3.  circulating tumor DNA AND clearance AND recurrence AND gastrointestinal
4.  liquid biopsy AND perioperative AND GI cancer AND prognosis
5.  ctDNA AND serial AND colorectal AND gastric AND pancreatic

• Status: All (include ongoing + completed + submitted)
• Date range: 2020 to present

What I found from my searches

Part 2 - Is This a Game-Changer? Clinical Significance Explained Simply

Yes, the concept is genuinely significant - here is why

The core promise

• CT scan every 3-6 months
• Blood tumor markers (CEA, CA19-9) every 3-6 months
• Wait for something to appear on imaging

The potential impact if adopted widely

• Patients in the "clearance" pattern group could potentially avoid unnecessary adjuvant chemotherapy (the DYNAMIC-III trial at ESMO 2025 showed ctDNA-guided de-escalation reduced oxaliplatin use from 88.6% to 34.8% with comparable survival outcomes - directly reducing toxicity and cost)
• Patients in the "conversion" or "persistent positive" group would get earlier treatment escalation
• This could fundamentally redefine what post-surgical surveillance looks like across all GI cancer types

Part 3 - Real-World Obstacles: Why This Is NOT Easily Practiced Everywhere

Obstacle 1 - Cost and infrastructure (the biggest barrier globally)

• Not covered by most insurance plans in most countries
• Completely inaccessible in low- and middle-income countries (LMICs) where most GI cancer surgery happens globally
• Covered only in select academic centers and clinical trials in high-income settings

Obstacle 2 - No standardization of assays (confirmed by the ctDNA Harmonization Project)

• Guardant Reveal, Foundation Medicine, Grail Signatera, Personal Genome Diagnostics, etc.
• Each uses different gene panels, different sensitivity thresholds, different positivity cutoffs
• A result of "ctDNA positive" on one platform does not mean the same thing as "ctDNA positive" on another

Obstacle 3 - Two large clinical trials just failed their primary endpoints (ESMO 2025)

• PEGASUS: ctDNA-guided arm showed 3-year RFS of 85.3% vs 88.1% in the standard arm - not statistically superior
• DYNAMIC-III: De-escalation of chemotherapy in ctDNA-negative patients was safe, but the trial did not prove that escalation in ctDNA-positive patients improved survival

Obstacle 4 - Low ctDNA shedding in some GI cancer types

• Colorectal cancer: relatively high shedder - good ctDNA detectability
• Pancreatic cancer: moderate to low shedder - ctDNA detected in only 40-60% of early-stage resected patients
• Neuroendocrine tumors: very low shedder - ctDNA almost undetectable
• Early-stage gastric cancer: low shedder pre-operatively

Obstacle 5 - Clonal hematopoiesis confounds results

1. Actual residual tumor DNA - means cancer is coming back
2. CHIP - a benign aging phenomenon - means nothing clinically

Obstacle 6 - The meta-analysis itself may be methodologically weak due to study heterogeneity

• Used different platforms (ddPCR, NGS, CAPP-Seq)
• Measured ctDNA at different timepoints (1 week post-op vs. 4 weeks vs. 3 months)
• Used different positivity thresholds (variant allele frequency 0.01% vs. 0.1%)
• Defined "clearance" differently across studies
• Had variable follow-up periods

Obstacle 7 - The research question may be "ahead of practice" rather than filling a practice-ready gap

"Even if you prove that serial ctDNA kinetics predict recurrence with a pooled HR of 50 for the conversion pattern - what do clinicians do with that? There is no proven intervention that improves survival in ctDNA-positive post-resection GI cancer patients outside of colorectal cancer, and even there the trials failed."

Summary: Honest Overall Assessment